Jun 15, 2020
Immunic, Inc. Announces First Patients Dosed in its Phase 2, CALVID-1 Clinical Trial of IMU-838 in COVID-19
May 12, 2020
Ulcerative Colitis Market Report 2020: Pipeline, Epidemiology, Competitive Analysis, Drug Sales and Shares through 2016-2024
May 07, 2020
InDex Pharmaceuticals Holding AB (publ) Interim Report January - March 2020
Apr 16, 2020
InDex Pharmaceuticals Advances Cobitolimod Further Towards Phase III Following Successful Interactions With FDA and EMA
Apr 09, 2020
Bridge Biotherapeutics Discloses Interim Results from the First Cohort of Phase 2a Study of BBT-401, an Experimental Drug for Ulcerative Colitis
Mar 31, 2020
InDex Pharmaceuticals Receives Grant From Vinnova for Pre-clinical Development of DIMS Compounds in Inflammation
Feb 25, 2020
InDex Pharmaceuticals Publishes Mechanism of Action Data for Cobitolimod in Scientific Journal
Feb 19, 2020
InDex Pharmaceuticals' In-depth Analysis of the CONDUCT Study Confirms the Successful Top Line Results and Supports the Strategy Going Forward
Jan 30, 2020
Genedata and the Crohn's & Colitis Foundation Collaborate to Improve Patient Care in Crohn's Disease
Jan 15, 2020
NuMedii, Inc. Announces Pharmaceutical Discovery Collaboration For Ulcerative Colitis
Dec 26, 2019
Bridge Biotherapeutics Announces China NMPA Clearance of IND for BBT-401, a Pellino-1 Inhibitor for UC
Nov 25, 2019
Immunic, Inc. to Participate in Investor and Scientific Conferences in December
Oct 22, 2019
Arena Pharmaceuticals Presented New Data Analyses Demonstrating the Long-Term Safety and Efficacy of Once-Daily Etrasimod in Patients with Moderately to Severely Active Ulcerative Colitis at UEG Week
Oct 17, 2019
Palatin Presents On Pl8177 Oral Colon Delivery Formulation For Ulcerative Colitis At The 7Th CPC Symposium On Peptide Therapeutics
Sep 05, 2019
Immunic, Inc.'s Interim Dosing Analysis of IMU-838 as Part of its Ongoing Phase 2 CALDOSE-1 Study in Patients with Moderate-to-Severe Ulcerative Colitis Establishes Broad, Potentially Safe and Effective Dose Range
Aug 28, 2019
Crohn's & Colitis Foundation's New England Chapter Commemorates 50th Anniversary of Support for Inflammatory Bowel Diseases
Aug 27, 2019
InDex Pharmaceuticals Meets Primary Endpoint in the Phase IIb Study CONDUCT with Cobitolimod in Ulcerative Colitis
Aug 01, 2019
Oral Alpha-4-Beta-7 Integrin Antagonist PN-943 Demonstrates Sustained Dose-Related Target Engagement Activity in a Multiple Ascending Dose Phase 1 Study
Jun 26, 2019
InDex Pharmaceuticals Gets New Patent in Europe
Jun 26, 2019
InDex Pharmaceuticals Enrolls Last Patient in Phase IIb Study CONDUCT With Cobitolimod